A 2026 Leigh syndrome study combined a cell-type-specific deep-learning screen with a 2,250-drug yeast survival screen and found the same drug family from both directions: azoles, with talarozole and sertaconazole lowering lactate release by 20% in SURF1-mutant midbrain organoids.1 The finding is preclinical, but it is stronger than a single in silico hit because the …
A 2026 Nature Neuroscience study from the Igarashi lab proposes a circuit-level answer for why the lateral entorhinal cortex (LEC) is the first cortical region to falter in Alzheimer’s: dopamine inputs from the VTA and substantia nigra to the LEC go functionally silent at the earliest disease stage in an APP knock-in mouse — before …
Dementia rates in the US, UK, Netherlands, Sweden, France, and several other high-income countries have been falling for decades, despite population aging. The standard explanation — improved cardiovascular care, more education, and less smoking in later-born cohorts — is real but incomplete. Research Highlights Dementia incidence has been falling about 13% per decade in Western …
A human, mouse, and zebrafish study linked long-term chlorpyrifos exposure to Parkinson’s disease risk, with the strongest exposure-duration estimate reaching OR 2.74 for workplace proximity across the 1974-to-index-year window.1 The paper is stronger than a single epidemiology result because animal experiments pointed to dopaminergic neuron loss, microglial activation, pathological α-synuclein, and autophagy dysfunction. Research Highlights …
A 2026 review in the Japanese Journal of Radiology argued that amyloid PET has moved from an optional Alzheimer’s disease biomarker to a practical eligibility gate for anti-amyloid antibody therapy, while tau PET and FDG-PET answer different questions in the same clinical workflow.1 The key shift is not that every memory complaint needs PET; it …
A 2026 humanized P301S tauopathy mouse study found that syntaxin-6 knockout partly rescued early motor impairment from months 1 to 4, protected gait at 5.5 months, reduced frailty (p = 0.0052), and reduced superficial-cortex neurodegeneration at 3 months (p = 0.0055).1 The finding strengthens syntaxin-6 as a tauopathy modifier, but it is still mouse genetics, …
A Nature Communications study found that old vertebrate brains lost almost 40% of cysteine protease deubiquitylase catalytic activity with age, despite relatively stable protein abundance.1 Antioxidant treatment with NACET restored DUB activity in aging brains, making the finding a reversible enzyme-mechanism result rather than a generic “antioxidants reverse brain aging” claim. Research Highlights DUB activity …